In the sedentary era, weight gain is becoming a serious preventable risk factor for increased body mass index which strongly correlates with enhanced cancer threat.
As reported cancers of endometrial, oesophageal adenocarcinoma, colorectal, postmenopausal breast, prostate & renal are caused due to surplus weight. The mechanism behind obesity and cancer partnership. The body’s lean shape is regulated by the delicate balance between adipocytes & immune cells. Chronic nutrient overload leads to adipocyte hypertrophy, mitochondrial dysfunction, increased oxidative & endoplasmic reticulum stress, proinflammatory signalling, adipokine secretion & cell death. Collectively instigate enhanced secretion of proinflammatory factors, dysregulated systemic metabolism, tumour growth, metastasis & progression.
• Alteration in an adipose stromovascular fraction
• Reduction in anti-inflammatory Treg & TH2 cells
• Increase in proinflammatory TH1 & CD8+T cells
• Variation in M2 to M1 macrophages
1. Adipokines - Weight gain alters the interaction between adipocytes, adipokine production
2. Adiponectin- Obesity triggers adiponectin reduction & causes a mutation in adiponectin receptors (ADIPOR1 & ADIPR2)
3. Leptin -Excessive weight facilitates leptin resistance & hyperlipidaemia, enables cell proliferation, migration, invasion responses, and tumour development
4. Estrogen- Increased weight fosters adipose-derived aromatase activity, estrogen production, systemic estrogen bioavailability, adipose-derived proinflammatory factors (IL-1β, IL-6, prostaglandin E2, and TNFα), liver-derived insulin growth factor 1 (IGF-1)
5. IL-6 and TNFα- Obesity-induced excess IL-6 and TNFα levels encourage cellular transformation, proliferation, invasion, angiogenesis, metastasis, cancer cell proliferation, survival & angiogenesis.
6. IL-1β- Heavy weight increases free fatty acid, cholesterol, blood sugar, and free radical’s levels stimulating tumour expression of IL-1β, NOD-like receptor family, pyrin domain containing 3 (NLRP3) & inflammasome activity
7. Osteopenia-Neoplastic transformation, cancer cell survival & metastasis progression enhances due to obesity-driven osteopenia phosphoprotein
8. YKL-40- Excessive obesity with diabetes generate YKL-40, cancer cell proliferation, angiogenesis, and extracellular matrix remodelling
9. PAI-1- Advancing obesity increases PAI-1 (serine protease inhibitor), cancer cell invasion, metastasis & tumours
10. Endotrophic -Increased adipose tissue promotes endotrophic production, activates TGF-β signalling, tumour cell growth & metastasis
• Central obesity causes insulin resistance, dyslipidaemia, hyperglycaemia & metabolic dysfunction
• Visceral adipose tissue aggravates the abdominal cavity’s momentum & produces more proinflammatory factors
Weight loss decreases infiltrating macrophages in adipose tissue inflammation, systemic complications of proinflammatory adipokines, obesity-linked pathologies & delays carcinogenesis. Dietary restriction-motivated weight loss reduces colorectal inflammation, decreases rectosigmoid expression of multiple proinflammatory cytokines and markers of T -cell, macrophage accumulation & attenuates cancer
pathways (FOS, JUN, STAT3, and NF-κB expression).
Visible weight loss reduces cancer risk, diminishes adipose-related inflammatory mechanisms, regulates tumour development & progression. Reduction and control of cancer risk demand a better understanding of cellular & molecular mechanisms behind obesity-induced inflammation, the proactive invention of early diagnosis biomarkers & accessible effective cancer therapy.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
2.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
3.
Recurrent UTIs impact eGFR in children with vesicoureteral reflux
4.
Month-Long Wait Times Caused by US Physician Shortage.
5.
Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.
1.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
2.
The Importance of Early Detection in Angiosarcoma: A Story of Survival
3.
Leukemia in Focus: Tools, Trials, and Therapy Strategies for Modern Medical Practice
4.
New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma
5.
Managing KRAS Inhibitor Toxicities: Focus on Rash and Beyond
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III
4.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation